Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.60 |
| ▸ | MAOA | P21397 | 7/20 | 0.56 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821225 | 0.88 | PARP10 (0.50) | PARP10PARP11HSD17B1MAOAMAOB | |
| SCHEMBL7506302 | 0.85 | HSD17B1 (0.71) | HSD17B1MAOAMAOBHRH3PRKCI | |
| SCHEMBL7584101 | 0.83 | HSD17B1 (0.73) | PARP10PARP11HSD17B1MAOAMAOB | |
| SCHEMBL315877 | 0.81 | MAOA (0.61) | HSD17B1MAOAMAOBPRKCIMAPK14 | |
| SCHEMBL4563338 | 0.81 | PARP10 (0.61) | PARP10PARP11HSD17B1MAOAMAOB | |
| SCHEMBL7509673 | 0.81 | HSD17B1 (0.56) | PARP10PARP11HSD17B1MAOAMAOB | |
| SCHEMBL4424565 | 0.81 | PARP10 (0.61) | PARP10PARP11HSD17B1MAOAMAOB | |
| SCHEMBL3021186 | 0.81 | HSD17B1 (0.74) | HSD17B1MAOAMAOBPRKCICYP1A2 | |
| SCHEMBL7507475 | 0.81 | HSD17B1 (0.56) | PARP10PARP11HSD17B1MAOAMAOB | |
| SCHEMBL4416659 | 0.81 | HSD17B1 (0.64) | HSD17B1MAOAMAOBHRH3PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10807956-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014100818-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-7319152-B2 | Contraception, hormone replacement therapy, cycle-related symptoms, or benign or malignant neoplastic disease; -methyl-5-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrole-2-carbonitrile | WYETH (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070066628-A1 | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-11214542-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-20070066628-A1 | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | PARP10 668/4885PARP11 1070/4885HSD17B1 113/4885 |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | PARP10 1176/4885PARP11 1124/4885HSD17B1 146/4885 |
| US-10807956-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | CYP19A1, PGR, NR5A1 | PARP10 2334/4885PARP11 1709/4885HSD17B1 58/4885 |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | CYP19A1, PGR, NR5A1 | PARP10 1904/4885PARP11 1253/4885HSD17B1 64/4885 |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
| US-10597365-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | PARP10 730/4885PARP11 508/4885HSD17B1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.